TP53mutations are frequent events in double-hit B-cell lymphomas withMYCandBCL2but notMYCandBCL6translocations

Double-hit B-cell Lymphomas With BCL6 and MYC Translocations Are Aggressive, Frequently Extranodal Lymphomas Distinct From BCL2 Double-hit B-cell Lymphomas

(2013) Raju K. Pillai et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases

(2013) Anamarija M. Perry et al.   BRITISH JOURNAL OF HAEMATOLOGY

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

(2012) Z. Y. Xu-Monette et al.   BLOOD

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

(2012) Roland Schmitz et al.   NATURE

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

(2011) F. G. Rucker et al.   BLOOD

Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

(2011) Nalan Akyurek et al.   CANCER

Mutational Status of theTP53Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial

(2011) David Gonzalez et al.   JOURNAL OF CLINICAL ONCOLOGY

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)

(2011) E Drakos et al.   LEUKEMIA

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome

(2011) Shaoying Li et al.   MODERN PATHOLOGY

B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma

(2010) Matija Snuderl et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Double-hit B-cell lymphomas

(2010) S. M. Aukema et al.   BLOOD

Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

(2010) Sharon Barrans et al.   JOURNAL OF CLINICAL ONCOLOGY

Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas

(2010) Adam C Seegmiller et al.   MODERN PATHOLOGY

Aggressive Lymphomas

(2010) Georg Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

The significance ofTP53in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target

(2009) K-John J. Cheung et al.   BRITISH JOURNAL OF HAEMATOLOGY

Blinded by the Light: The Growing Complexity of p53

(2009) Karen H. Vousden et al.   CELL

Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

(2009) N Niitsu et al.   LEUKEMIA

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study

(2008) K. H. Young et al.   BLOOD

Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma

(2008) Heli Pennanen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY